Olmesartan/Amlodipin Al (Amlodipine, Olmesartan)

Olmesartan, the active ingredient in Olmesartan/Amlodipin Al, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension in adult patients, often in combination with a calcium‑channel blocker. GNH USA supplies Olmesartan/Amlodipin Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan/Amlodipin Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipin Al is used primarily for hypertension management through its dual‑action on the renin‑angiotensin system and vascular smooth‑muscle tone. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension with high‑risk cardiovascular profile: provides additional protection against stroke and myocardial infarction. - Hypertensive patients who require combination therapy: simplifies treatment by combining an ARB with a calcium‑channel blocker.

Adverse reactions may occur with any antihypertensive regimen and should be monitored during therapy.

Common Side Effects: - Peripheral edema: mild swelling of the ankles or feet. - Headache: transient tension‑type headaches. - Dizziness: especially on standing. - Flushing: warm sensation on the face or neck. - Fatigue: general tiredness. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of lips, tongue or airway. - Severe hypotension: symptomatic low blood pressure. - Hepatic dysfunction: elevated liver enzymes. - Acute kidney injury: sudden rise in serum creatinine. - Myocardial infarction: rare but reported in vulnerable patients. - Stevens‑Johnson syndrome: severe skin reaction.

When prescribing Olmesartan/Amlodipin Al, clinicians should consider several safety aspects. - Renal impairment: adjust dose or monitor renal function regularly. - Hepatic impairment: use with caution in patients with liver disease. - Electrolyte disturbances: monitor potassium and sodium levels. - Pregnancy: contraindicated in the second and third trimesters. - Concomitant strong CYP3A4 inhibitors: may increase amlodipine exposure. Store at ambient temperature: keep the ...

The combination product may ...